FDA Advisory Committee Nixes Trevena’s Opioid in Tight Vote

Drug Industry Daily
A A
An FDA advisory panel narrowly voted Thursday not to recommend approval of Trevena’s NDA for oliceridine, an opioid treatment for moderate-to-severe acute pain in adults.

To View This Article:

Login

Subscribe To Drug Industry Daily